# Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

> **NCT03328104** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 8 (actual)

## Conditions studied

- Lymphoblastic Leukemia
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Nelarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03328104
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-24
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-06-29
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328104, "Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03328104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*